<DOC>
	<DOC>NCT00719680</DOC>
	<brief_summary>The purpose of this study is to determine whether a long-term use of a new human immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary immunodeficiency.</brief_summary>
	<brief_title>Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Subjects with primary humoral immunodeficiency who have participated in the study ZLB04_009CR (NCT00419341), namely with a diagnosis of Common Variable Immunodeficiency (CVID) as defined by PAGID (PanAmerican Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or Xlinked Agammaglobulinemia (XLA) as defined by PAGID and ESID Women of childbearing potential must be using and agree to continue using medically approved contraception and must have a negative pregnancy test at screening Written informed consent Ongoing serious bacterial infection at the time of screening Malignancies of lymphoid cells such as lymphocytic leukemia, NonHodgkin's lymphoma, and immunodeficiency with thymoma Hypoalbuminemia, proteinlosing enteropathies, and any proteinuria (defined by total urine protein concentration &gt; 0.2 g/L) Other significant medical conditions that could increase the risk to the patient Females who are pregnant, breastfeeding or planning a pregnancy during the course of the study A positive result at screening on any of the following viral markers: Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) or Hepatitis B virus (HBV) Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) concentration &gt; 2.5 times Upper Normal Limit (UNL) at Completion Visit of study ZLB04_009CR (NCT00419341) Creatinine concentration &gt; 1.5 times UNL at Completion Visit of study ZLB04_009CR (NCT00419341) Participation in a study with an investigational product other than IgPro20 within 3 months prior to enrollment Evidence of uncooperative attitude Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial Subjects who are employees at the investigational site, relatives or spouse of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>CVID</keyword>
	<keyword>XLA</keyword>
</DOC>